Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALS Over 3 years, a subset of QALSODY-treated participants ...
The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Neurofilament light chain and cerebrospinal fluid ...
The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis ...
108 MND patients known to have the faulty SOD1 gene took part in the pioneering Phase 3 clinical trial funded by biotechnology company Biogen Inc. Although a significant clinical improvement was not ...
Share on Pinterest Researchers are hopeful that a new drug can help treat the symptoms of a rare type of ALS. herraez/Getty Images The Food and Drug Administration (FDA) has approved the drug toferson ...
Apic Bio Receives FDA Fast Track Designation for APB-102 for the Treatment of Patients with SOD1 ALS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that the U.S. Food and ...
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results